The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis
BMC Nephrology, 2020 Background The safety of antiplatelet therapy in haemodialysis (HD) patients remains controversial. we conducted the first meta-analysis to evaluate the bleeding risk with antiplatelet agents in these populations.
Qi Wang, Xiaojie Xie, Gaosi Xu
doaj +2 more sources
Hepatology Communications, 2018 Platelets participate in the development of liver fibrosis in animal models, but little is known about the benefit of antiplatelet agents in preventing liver fibrosis in humans.
Katharina Schwarzkopf +9 more
doaj +2 more sources
Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. [PDF]
Ann Med, 2022 Background Serotonin reuptake inhibitor (SRI) antidepressants are implicated in increasing the risk of bleeding among users; however, the comparative increase in bleeding risk with concurrent antithrombotic therapy (anticoagulant or antiplatelet) remains
Nochaiwong S +9 more
europepmc +2 more sources
Efficacy and Safety of Antiplatelet Agents for Adult Patients With Ischemic Moyamoya Disease
Frontiers in Neurology, 2021 Background: The use of antiplatelet agents in ischemic moyamoya disease (MMD) is controversial. This study aimed to investigate the effectiveness and safety of antiplatelet therapy compared with conservative treatment and surgical revascularization in ...
Fei Ye +12 more
semanticscholar +1 more source
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review
Open Heart, 2021 Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic and thromboembolic events.
K. Matli +5 more
semanticscholar +1 more source
Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update
Current Anesthesiology Reports, 2022 Purpose of Review Multiple guidelines and recommendations have been written to address the perioperative management of antiplatelet and anticoagulant drugs.
Michael Moster, D. Bolliger
semanticscholar +1 more source
COVID-19 mortality in patients on anticoagulants and antiplatelet agents. [PDF]
Br J Haematol, 2020 Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D-dimer and fibrinogen levels (Al-Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Sivaloganathan H +2 more
europepmc +2 more sources
Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Frontiers in Neurology, 2021 Stroke is one of the world's leading causes of disability and death. Antiplatelet agents are administered to acute ischemic stroke patients as secondary prevention.
Adel Alhazzani +6 more
doaj +1 more source
NEW ANTIPLATELET DRUGS (PART 1)
Рациональная фармакотерапия в кардиологии, 2016 Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding ...
A. B. Sumarokov
doaj +3 more sources
Novel Antiplatelet Agents in Cardiovascular Disease
Journal of Cardiovascular Pharmacology and Therapeutics, 2020 Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone in the treatment of cardiovascular disease. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the thrombin receptor ...
M. Tscharre +2 more
semanticscholar +1 more source